# US 2008/0306131 A1 · Progesterone receptor modulator and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306131 A1
- Document ID: US20080306131A1
- Status: Published application
- Kind: A1
- Application number: 12/156,504
- Filed: 2008-06-02
- Published: 2008-12-11
- Earliest claimed: 2007-06-05
- Assignees: Wyeth
- Inventors: Laurel Rita Barbieri; Thomas Joseph Berrodin; Ramunas Bigelis; Li-Ping Chang; Deborah Marie Roll; Maya Prakash Singh; Matthew R. Yudt
- Web page: https://patentgrep.com/patent/US20080306131A1

## CPC

- C12P 17/10: Nitrogen as only ring hetero atom
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 209/94: containing carbocyclic rings other than six-membered
- C12N 1/145: Fungi isolates
- C12R 2001/645: Fungi {; Processes using fungi}
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Compounds of the structure: are provided. Also provided are methods of using these compounds as progesterone receptor modulators. Also described are methods of producing these compounds from a Verticillium species.

## Claims

### Claim 1

A compound having the structure:
R1 is H or OH;
R2 is H or
R3 is H or CH3;
R4, R5 is ═O, OH;
R6, R7 is CH═CH, CH2—CH2, OH, and an epoxide,
or a pharmaceutically acceptable salt, ester, or ether thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, selected from the group consisting of:
or a pharmaceutically acceptable salt or ester thereof.

### Claim 3

A compound having the characteristics:
(a) molecular formula C23H27NO2;
(b) a molecular weight characterized by a high resolution ion electrospray MS m/z of 350.21161 (M+H)+ and a negative ion electrospray MS m/z of 348.2; and
(c) an ultraviolet absorption spectrum of λmax nm
(acetonitrile/water/formic acid) of 234, 284.

### Claim 4 (depends on 3)

The compound of claim 3 further characterized by
a proton nuclear magnetic resonance (400 MHz; δ, CDCl3): 7.92, 7.49, 7.35, 7.31, 7.12, 7.11, 6.18, 2.85, 2.77, 2.43, 2.07, 1.96, 1.84, 1.80, 1.51, 1.40, 1.32, 1.25; and
a carbon nuclear magnetic resonance (100 MZ; δ, CDCl3): 203.9, 155.2, 152.3, 140.3, 128.4, 125.4, 121.1, 118.9, 118.1, 111.8, 80.4, 53.4, 52.3, 49.6, 48.2, 29.7, 28.4, 27.5, 25.6, 23.7, 21.4, 19.8.

### Claim 5 (depends on 3)

The compound of claim 3, which is 4a-hydroxy-4,4,12b,12c-tetramethyl-4a,5,6,6a,7,12,12b,12c-octahydrobenzo[6,7]indeno[1,2-b]indol-3(4H)-one.

### Claim 6

A compound having the characteristics:
(a) a molecular formula: C23H29NO2;
(b) a molecular weight characterized by a high resolution positive ion electrospray MS m/z=352.22700 (M+H)+ and a high resolution negative ion electrospray MS m/z=350.21242 (M−H)−; and
(c) an ultraviolet absorption spectrum of λmax nm (acetonitrile-water-formic acid)=232, 284.

### Claim 7 (depends on 6)

The compound according to claim 6 further characterized by
a proton nuclear magnetic resonance of (400 MHz; δ, CHCl3):
7.73, 7.44, 7.31, 7.09, 7.08, 2.92, 2.82, 2.75, 2.74, 2.72, 2.42, 2.03, 1.97, 1.73, 1.65, 1.63, 1.34, 1.27, 1.25, 1.13; and
a carbon nuclear magnetic resonance of (100 MHz; δ, CDCl3): 216.8, 152.7, 140.2, 125.4, 120.8, 119.9, 118.8, 117.4, 111.7, 81.5, 54.9, 53.3, 49.5, 43.7, 34.7, 32.5, 29.9, 27.7, 24.5, 23.1, 22.6, 21.3, 17.0.

### Claim 8 (depends on 6)

The compound according to claim 6 which is 4a-hydroxy-4,4,12b,12c-tetramethyl-1,4,4a,5,6,6a,7,12,12b,12c-decahydrobenzo[6,7]indeno[1,2-b]indol-3(2H)-one.

### Claim 9

A compound having the characteristics:
(a) a molecular formula of C30H39NO7;
(b) a molecular weight of positive ion electrospray MS m/z=526.2 (M+H)+; negative ion electrospray MS m/z=524.9 (M−H)−; and
(c) an ultraviolet absorption spectrum of λmax nm (acetonitrile-water-formic acid)=236, 278, 300.

### Claim 10 (depends on 9)

The compound according to claim 9, further characterized by
a proton nuclear magnetic resonance (400 MHz; δ, CDCl3): 8.01, 7.33, 7.24, 7.07, 6.86, 6.03, 4.88, 3.94, 3.77, 3.75, 3.68, 3.62, 3.44, 3.30, 2.76, 2.31, 1.87, 1.80, 1.71, 1.56, 1.32, 1.26, 1.22, 1.12, 1.07.

### Claim 11 (depends on 9)

The compound according to claim 9, which is (4aS,6aR,12bR,12cR)-4,4,12b,12c-tetramethyl-3-oxo-3,4,4a,5,6,6a,7,12,12b,12c-decahydrobenzo[6,7]indeno[1,2-b]indol-10-yl 4-O-methyl-α-D-glucopyranoside.

### Claim 12

A compound characterized by
(a) a molecular formula of C23H31NO2;
(b) a molecular weight characterized by a high resolution ESI FTMS m/z=354.24264 (M+H)+; high resolution ESI FTMS m/z=352.22817 (M−H)−; and
(c) an ultraviolet absorption spectrum of λmax nm (acetonitrile-water-formic acid)=234, 284.

### Claim 13 (depends on 12)

The compound according to claim 12, further characterized by a proton nuclear magnetic resonance (400 MHz; δ, CDCl3):
7.72, 7.43, 7.30, 7.08, 7.07, 3.62, 2.84, 2.69, 2.66, 2.38, 2.30, 2.00, 1.87, 1.74, 1.72, 1.68, 1.38, 1.25, 1.24, 1.14, 1.03; and
a carbon nuclear magnetic resonance (100 MHz; δ, CDCl3): 154.3, 139.9, 125.6, 120.4, 119.7, 119.6, 117.3, 111.6, 81.5, 78.5, 54.9, 49.6, 43.9, 42.4, 30.5, 27.7, 26.7, 25.3, 24.8, 24.4, 23.4, 21.9, 17.0.

### Claim 14 (depends on 12)

The compound according to claim 12, which is (3S,4aR,6aR,12bR,12cS)-4,4,12b,12c-tetramethyl-1,3,4,5,6,6a,7,12,12b,12c-decahydrobenzo[6,7] indeno[1,2-b]indole-3,4a(2H)-diol.

### Claim 15 (depends on 1)

A process for the preparation of a compound of claim 1 which comprises culturing a strain of Verticillium lecanii capable of producing the compound and isolating the compound.

### Claim 16 (depends on 1)

The process according to claim 1, wherein the compound is isolated by multiple reversed-phased column chromatography of fermentation extracts prepared by soaking in methanol.

### Claim 17

An isolated culture of Verticillium lecanii strain ARSEF 6144-A, assigned Agricultural Research Service Culture Collection (NRRL) Accession No. NRRL 30907.

### Claim 18 (depends on 17)

A progesterone receptor modulator isolated from the culture of claim 17.

### Claim 19

A method of producing a progesterone receptor modulator compound comprising the step of culturing Verticillium lecanii strain ARSEF 6144-A under conditions suitable to produce the compound.

### Claim 20 (depends on 1)

A progesterone receptor modulator composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 21 (depends on 1)

A method of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, and treating or preventing benign or malignant neoplastic disease comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 1.

### Claim 22 (depends on 21)

The method according to claim 21 wherein said cycle-related symptoms are psychological.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said psychological symptoms include mood changes, irritability, anxiety, lack of concentration, or decrease in sexual desire.

### Claim 24 (depends on 21)

The method according to claim 21, wherein said cycle-related symptoms are physical.

### Claim 25 (depends on 24)

The method according to claim 24, wherein said physical symptoms include breast tenderness, bloating, fatigue, cramping, irregular menstrual bleeding, or food cravings.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the hormone-dependent neoplastic disease is selected from the group consisting of uterine fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, and meningioma.

### Claim 27 (depends on 1)

A method of treating neurodegenerative disorders comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 1.

### Claim 28 (depends on 22)

The method according to claim 22, wherein the neurodegenerative disorders are selected from the group consisting of Alzheimer's disease, Parkinson's disease, and neuronal damage following ischemia or trauma.
